Predictive biomarkers for first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC) have been proposed, but none have been validated using data from a randomized controlled trial (RCT), which is the only design capable of unbiased assessment of differential treatment effect (DTE)....
W. Quan, D. Henault, S. M. Hasnain et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at an advanced stage with limited treatment options. Patient-derived organoids (PDOs) can model tumors, identify determinants of therapeutic response, and support precision medicine. In the multi-institutional PASS-01 trial of metastatic PDAC, biopsies f...
A. Habowski, Fatim M. Kouassi, James A. Rouse et al.· Cancer Research· 0 citations
This work modeled resistance using patient-derived xenografts from two PDACs harboring pathogenic germline BRCA2 variants, and identified convergent transcriptional and epigenetic cell states associated with BRCA2-reversion-independent platinum/PARPi resistance in PDAC.
J. Romero, Yi-Fan Wang, Edward Shanbedi et al.· Cancer Research· 0 citations
A systematic discovery pipeline focused on families with multiple affected individuals, leveraging familial segregation and matched tumor analysis to identify novel hereditary PDAC susceptibility genes, highlighting the complexity of hereditary PDAC and support continued genetic and functional evaluation of the priorit...
Jing-Xiong Xu, Y. Goldberg, Amy Zhang et al.· Cancer Research· 0 citations
MULTIPL demonstrated robust prognostic performance in external validation, identified a subgroup enriched for benefit from GNP, and enabled discovery and validation of prognostic biomarkers in metastatic PDAC, underscoring the value of the PASS-01 Challenge.
W. Quan, D. Henault, A. Zhang et al.· medRxiv· 0 citations
Better patient selection for treatment is critical to improving both cancer care and therapeutic development in oncology. The ability to predict individual patient responses to cancer treatment ahead of time would transform cancer care with substantial impact on outcomes, quality of life and cost. We generated molecula...
M. Griffiths, Jennifer J. Knox, G. O'Kane et al.· Frontiers in Artificial Inte...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.